Noboru Yamamoto, Takafumi Koyama, Jun Sato, Tatsuya Yoshida, Kazuki Sudo, Satoru Iwasa, Shunsuke Kondo, Kan Yonemori, Atsuko Kawasaki, Kyoko Satake, et al. Correction to: Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors. Cancer chemotherapy and pharmacology. 2024. 94. 3. 491-491
Pierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, Arnaud Pigneux, Junichiro Yuda, Mahipal Sinnollareddy, William R Henner, Diana Chen, Kevin J Freise, Rachel S Leibman, et al. First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC. Expert review of anticancer therapy. 2024. 24. 9. 893-904
Takafumi Koyama, Kan Yonemori, Toshio Shimizu, Jun Sato, Shunsuke Kondo, Kazuki Sudo, Tatsuya Yoshida, Yuki Katsuya, Tatsuki Imaizumi, Masashi Enomoto, et al. Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors. Cancer research communications. 2024. 4. 9. 2349-2358
Toshiaki Takakura, Hiroaki Akamatsu, Atsushi Washioka, Eriko Murakami, Ryota Shibaki, Toshio Shimizu, Yasuhiro Koh, Nobuyuki Yamamoto. Unsuccessful rechallenge with nivolumab in a patient with advanced non-small cell lung cancer who had a 6-year complete response and treatment-free period: Case report. Respirology case reports. 2024. 12. 9. e01401
Toshiaki Takakura, Toshio Shimizu, Nobuyuki Yamamoto. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy. Japanese journal of clinical oncology. 2024. 54. 8. 837-846
A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignancies
(The 73rd Annual Meeting of the Japanese Cancer Association (JCA) 2014)
Phase I study of YM155, selective survivin suppressant plus elrotnib in patients with EGFR-mutant advanced non-small-cell lung cancer (NSCLC)
(The 12th Annual Meeting of Japanese Society of Medical Oncology 2014)
2019/10 - Chinese Society of Clinical Oncology (CSCO) CSCO 2019 Travel Grant Award 受賞
2011/06 - ASCO(米国臨床腫瘍学会) ASCO(米国臨床腫瘍学会)2011 Merit Award 受賞 The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase 1 study
所属学会 (8件):
日本製薬医学会
, 日本臨床薬理学会
, 日本肺癌学会
, JSMO(日本臨床腫瘍学会)
, 日本内科学会
, ASCO (American Society of Clinical Oncology)
, ESMO (European Society of Medical Oncology)
, AACR (American Association of Cancer Research)